

Clinical trials of ivabradine 15mg

TrialResults-center www.trialresultscenter.org

1 stable angina

Trial	Treatments	Patients	Trials design and methods
ivabradine 15mg vs placebo			
BEAUTIFUL , 2008 [NCT00143507] n=5479/5438 follow-up: 19 months (range 16-24)	ivabradine target dose of 75 mg twice a day versus placebo	patients with coronary artery disease and left-ventricular systolic dysfunction (LVEF <=40%)	double blind 33 countries
ivabradine 15mg vs placebo (on top standard treatment)			
BEAUTIFUL (angina subgroup) n=734/773 follow-up: 19 months (range 16-24)	ivabradine target dose of 75 mg twice a day versus placebo	patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina	double blind 33 countries
ivabradine 15mg vs placebo on top of amlodipine			
CL3-018 15mg , 3000 <i>unpublished</i> n=244/252	ivabradine 7.5mg twice daily (15mg/d) versus placebo	-	
ivabradine 15mg vs placebo on top of atenolol			
ASSOCIATE (Tardif) , 2009 [NCT00202566] n=449/440 follow-up: 4 months	ivabradine 5 mg b.i.d. for 2 months, increased to 7.5 mg b.i.d. for a further 2 months (on top atenolol 50 mg/day) versus placebo on top atenolol 50 mg/day	patients with stable angina receiving atenolol 50 mg/day or another beta-blocker at equivalent doses for at least 3 months	Parallel groups double blind 20 countries
ivabradine 15mg vs amlodipine			
Ruzylo (CL3-023) 15mg , 2007 n=400/404 follow-up: 3 months	ivabradine 7.5mg twice daily versus amlodipine 10mg once daily	Patients with a >/=3-month history of chronic, stable effort-induced angina	Parallel groups double-blind
ivabradine 15mg vs atenolol			

continued...

Trial	Treatments	Patients	Trials design and methods
INITIATIVE (CL3-017, Tardif) 15mg , 2005 n=315/307 follow-up: 16 weeks	ivabradine 5 mg bid for 4 weeks and then either 7.5 or 10 mg bid for 12 weeks versus atenolol 50 mg od for 4 weeks and then 100 mg od for 12 weeks	patients with stable angina	double-blind

More details and results :

- HR-slowing agents for stable angina in patients with left ventricular dysfunction at <http://www.trialresultscenter.org/go-Q118>
- HR-slowing agents for stable angina in all type of patients at <http://www.trialresultscenter.org/go-Q262>

References

BEAUTIFUL, 2008:

Fox K, Ford I, Steg PG, Tendera M, Ferrari R Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. *Lancet* 2008 Sep 6;372:807-16 [[18757088](#)]

BEAUTIFUL (angina subgroup), :

Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. *Eur Heart J* 2009 Oct;30:2337-45 [[19720635](#)]

CL3-018 15mg, 3000:

unpublished

ASSOCIATE (Tardif), 2009:

Tardif JC, Ponikowski P, Kahan T Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. *Eur Heart J* 2009 Mar;30:540-8 [[19136486](#)]

Ruzylo (CL3-023) 15mg, 2007:

Ruzylo W, Tendera M, Ford I, Fox KM Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. *Drugs* 2007;67:393-405 [[17335297](#)]

INITIATIVE (CL3-017, Tardif) 15mg, 2005:

Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. *Eur Heart J* 2005 Dec;26:2529-36 [[16214830](#)]

2 heart failure

Trial	Treatments	Patients	Trials design and methods
ivabradine 15mg vs placebo			
BEAUTIFUL , 2008 [NCT00143507] n=5479/5438 follow-up: 19 months (range 16-24)	ivabradine target dose of 75 mg twice a day versus placebo	patients with coronary artery disease and left-ventricular systolic dysfunction (LVEF <=40%)	double blind 33 countries

More details and results :

- HR-slowng agents for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q456>

References

BEAUTIFUL, 2008:

Fox K, Ford I, Steg PG, Tendera M, Ferrari R Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008 Sep 6;372:807-16 [18757088]

Entry terms: ivabradine, ivabradine, Corlanor, Procorolan, S 16257-2, S-16257-2, S-16260-2, S 16260-2, S 16257, S-16257,